Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii

作者：Yakun Fu, Tomefa E. Asempa, Joseph L. Kuti · 发表于：Expert Review of Anti-infective Therapy · 年份：2024 · DOI：10.1080/14787210.2024.2440018 · 被引用次数：13 · 研究领域：Antibiotic Resistance in Bacteria、Nosocomial Infections in ICU、Antibiotics Pharmacokinetics and Efficacy

Introduction Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against CRAB. The phase III randomized trial (ATTACK) demonstrated the safety and efficacy of sulbactam-durlobactam in combination with imipenem – cilastatin as background therapy in treating adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by CRAB.Areas covered This review will discuss pharmacology, antimicrobial activity, pharmacokinetics/pharmacodynamics, clinical efficacy, safety, and therapeutic role of sulbactam-durlobactam. To gather relevant information, a literature search was performed using PubMed and Google Scholar electronic databases. Search terms used include sulbactam, sulbactam-durlobactam, ETX2514, Acinetobacter baumannii, Acinetobacter baumannii-calcoaceticus complex, CRAB, OXA-24, and OmpA. Additional information was obtained from sulbactam-durlobactam FDA package insert and infectious diseases conference abstracts.Expert opinion Sulbactam-durlobactam is a well-tolerated β-lactam-β-lactamase inhibitor combination agent with efficacy against CRAB. Given the limitations of alternative treatment options, sulbactam-durlobactam may also be consider...